GENE ONLINE|News &
Opinion
Blog

2021-07-10| Asia-Pacific

Sparx Therapeutics to Build a Massive Manufacturing Plant in China for Multi-Specific Antibody Production

by Tyler Chen
Share To

Founded just around 3 years ago, a small Chicago biotech is prepared to build a huge production center in the Yangzhou Economic Zone, China, to increase manufacturing capacity for its antibody-drug pipelines.

On July 8th, Sparx Therapeutics announced the plan to establish a 1.2 million-square-foot plant in China and is estimated to begin operating at the end of 2022.

 

Increasing Capacity for Commercial Production

The new plant in China will include a 400,000-square-foot cGMP cleanroom and a total bioreactor capacity of 80,000-liters in separate cleanroom suites. The goal is to produce five commercial products simultaneously and fulfill the needs of chemistry, manufacturing, and controls (CMC) for over 12 programs in clinical trials.

“The planned facilities, with a total bioreactor capacity of 80,000-liters, will provide sufficient quantities of drug substances and drug products to support preclinical and clinical development and ultimately commercial launch”, said Dr. Gui-Dong Zhu, CEO of Sparx.

 

Targeting Solid Tumors with Multi-Specific Antibody

Sparx develops multi-specific antibody and antibody-drug conjugate (ADC) discovery platforms to target solid tumors such as gastric and colon cancer. 

Currently, the firm has three first-in-class candidates in the preclinical stage and three candidates ready for an investigational new drug (IND) application. Its R&D power has also attracted Eli Lilly’s distinguished research fellow, Dr. Victor Wroblewski, to join as the senior VP and the head of biology.

Aside from the expected plant in Yangzhou Economic Zone, Sparx has in-house facilities in Chicago and China to manufacture clinical and commercial drug substances but feels the need to expand as they couldn’t meet the development needs for antibody production, especially commercial use.

Related Article: Gilead’s Yescarta Becomes First CAR-T Therapy to Score Regulatory Approval in China

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Highlights from ESMO 2024: Key Oncology Advances from Major Pharmaceutical Companies
2024-09-19
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
China Approves AstraZeneca’s Fasenra for Severe Eosinophilic Asthma
2024-08-21
LATEST
Bayer’s NUBEQA: Breakthrough in Prostate Cancer with 46% Risk Reduction and Future FDA Expansion Plans
2024-09-19
Highlights from ESMO 2024: Key Oncology Advances from Major Pharmaceutical Companies
2024-09-19
Five Biotech Stocks Soar: Eyes on Halozyme, United Therapeutics, Harmony, Ligand, and ADMA
2024-09-19
Biotech Industry Trends in 2024: A Look at the Billions in Oncology Deals
2024-09-18
Thailand’s Biotech Boom: Innovations in Precision Medicine, Cell Therapy, and Wellness Drive APAC Leadership
2024-09-18
International Green Party Showcases AI Solutions for a Healthy and Sustainable Future
2024-09-16
Bio Asia Pacific 2024 Close ASEAN Collaborations: Catalyzing Innovation and Global Partnerships
2024-09-12
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top